56 related articles for article (PubMed ID: 36003920)
1. miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.
Sun Z; Ren M; Niu J; Tang G; Li Y; Kong F; Song X
Environ Toxicol; 2024 Apr; ():. PubMed ID: 38587027
[TBL] [Abstract][Full Text] [Related]
2. Induction of resistance to oxaliplatin in cancer by a microRNA/Fem1B/Gli1 pathway.
Su YC; Metzen LT; Vélez LM; Bournique E; Seldin M; Buisson R; Kuo WW; Huang CY; Kaiser P
Am J Cancer Res; 2023; 13(12):6011-6025. PubMed ID: 38187042
[TBL] [Abstract][Full Text] [Related]
3. MiR-29b regulates Th2 cell differentiation in asthma by targeting inducible B7-H3 and STAT3.
Gu W; Li G; Zhang W; Zhang X; He Y; Huang L; Yan Y; Ji W; Hao C; Chen Z
Clin Transl Allergy; 2022 Jan; 12(1):e12114. PubMed ID: 35079347
[TBL] [Abstract][Full Text] [Related]
4. A Study of FoxO1, mTOR, miR-21, miR-29b, and miR-98 Expression Levels Regarding Metabolic Syndrome in Acne Vulgaris Patients.
Akdağ N; Atli E; Zhuri D; Sezgi Ner Güler H; Gürsel Ürün Y
Cureus; 2024 Mar; 16(3):e56562. PubMed ID: 38646331
[TBL] [Abstract][Full Text] [Related]
5. A recurrent missense variant in the E3 ubiquitin ligase substrate recognition subunit FEM1B causes a rare syndromic neurodevelopmental disorder.
Lecoquierre F; Punt AM; Ebstein F; Wallaard I; Verhagen R; Studencka-Turski M; Duffourd Y; Moutton S; Tran Mau-Them F; Philippe C; Dean J; Tennant S; Brooks AS; van Slegtenhorst MA; Jurgens JA; Barry BJ; Chan WM; England EM; Martinez Ojeda M; Engle EC; Robson CD; Morrow M; Innes AM; Lamont R; Sanderson M; Krüger E; Thauvin C; Distel B; Faivre L; Elgersma Y; Vitobello A
Genet Med; 2024 Mar; 26(6):101119. PubMed ID: 38465576
[TBL] [Abstract][Full Text] [Related]
6. Retracted: miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9858543. PubMed ID: 37829534
[TBL] [Abstract][Full Text] [Related]
7. miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.
Zhang H; Wang R; Deng Q
Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
[TBL] [Abstract][Full Text] [Related]
8. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway.
Zhu L; Chen Y; Liu J; Nie K; Xiao Y; Yu H
Cancer Biomark; 2020; 29(3):347-357. PubMed ID: 32716350
[TBL] [Abstract][Full Text] [Related]
10. MiroRNA-31-3p Promotes the Invasion and Metastasis of Non-Small-Cell Lung Cancer Cells by Targeting Forkhead Box 1 (FOXO1).
Zeng X; Liu D; Peng G; Liu J; Yang H
Comput Math Methods Med; 2022; 2022():4597087. PubMed ID: 35126623
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN.
Wang H; Guan X; Tu Y; Zheng S; Long J; Li S; Qi C; Xie X; Zhang H; Zhang Y
J Exp Clin Cancer Res; 2015 Jun; 34(1):59. PubMed ID: 26063204
[TBL] [Abstract][Full Text] [Related]
13. miR-29b attenuates histone deacetylase-4 mediated podocyte dysfunction and renal fibrosis in diabetic nephropathy.
Gondaliya P; P Dasare A; Jash K; Tekade RK; Srivastava A; Kalia K
J Diabetes Metab Disord; 2020 Jun; 19(1):13-27. PubMed ID: 32550152
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
